SlideShare une entreprise Scribd logo
1  sur  41
Télécharger pour lire hors ligne
Asthma phenotypes and endotypes
Asthma Phenotypes
and Endotypes

Gamal Rabie Agmy, MD, FCCP
Professor of chest Diseases, Assiut university
Definition of Asthma


A chronic inflammatory disorder of the airways



Many cells and cellular elements play a role



Chronic inflammation is associated with airway
hyperresponsiveness that leads to recurrent
episodes of wheezing, breathlessness, chest
tightness, and coughing



Widespread, variable, and often reversible
airflow limitation
Asthma Inflammation: Cells and Mediators

Source: Peter J. Barnes, MD

Asthma is a complex disease or a syndrome

that includes several disease variants.
The term asthma, like ‘arthritis’, equates to a
definition of grouped clinical and physiological
characteristics. These characteristics could

identify

syndromes,

phenotypes

or

even

multiple diseases rather than a single disease.
◙ For

revealing the complexity and the

heterogeneity of this disease, asthma patients
were grouped into subtypes called phenotypes.

◙ Term ‘phenotype’ describes subtypes of
asthma focused on

‘clinically observable

characteristics’ of a disease.
Asthma phenotypes and endotypes
Asthma phenotypes and endotypes
Asthma phenotypes and endotypes
Therefore, there are many ‘definitions’ for asthma phenotypes,
many of which are related to differences in symptoms and

severity rather than to differences in underlying mechanisms. but
this kind of subtyping does little to help understand prognosis
and target therapy.

When a link can be made between clinical characteristics and
molecular pathways,

the term endotype

can be introduced

to describe distinct subtypes with a defining etiology and

consistent pathobiologic mechanisms.
The definition of a true phenotype (or endotype)
requires

an

underlying

pathobiology

with

identifiable biomarkers and genetics .

Gene-expression profiling

allows definition of

expression signatures to characterize patient
subgroups, predict response to treatment, and
offer novel therapies.
Th2-associated asthma
These patients are characterized by atopy,
eosinophilic inflammation and favorable response
to corticosteroids.

Early-onset allergic asthma
Late-onset persistent eosinophilic asthma
Exercise induced asthma
Early-onset allergic asthma
Clinical characteristics:
This group of asthmatic patients developed their disease in
childhood, and maintained their symptoms into adulthood. .
The majority of early-onset allergic asthma is mild but that

an increasing complexity of immune processes leads to
greater severity.
Most people with asthma are likely to have this phenotype.
Positive skin prick tests, specific IgE antibodies in serum,
eosinophilia in the peripheral blood .
Genetics:
Early-onset allergic patients commonly have a
family history of asthma, suggesting a genetic
component.
►Several Th2 cytokine SNPs

►higher numbers of mutations in TH2-related genes
(IL4, IL13, IL4Rα ) associated with greater severity
of disease.
Biomarkers:
Positive SPT, elevated IgE/elevated FeNO

Th2 cytokines IL-4 ,IL-5 , IL-9, IL-13, and periostin measured in
sputum, BAL, serum and bronchial biopsies.

Treatment responses:
►Corticosteroid-responsive.
►Th2 Targeted therapy:
Anti IgE (omalizumab)in Severe allergic asthma.

Anti–IL-13( lebrikizumab) in Allergic asthma with dominant IL13 activation . Surrogate marker predicting better response is

high circulating levels of periostin. .
Inhaled IL-4Rα antagonist

. Surrogate

marker predicting better response is IL-4
receptor a polymorphism.
Late-onset persistent eosinophilic asthma
Clinical characteristics:
The majority of this group develops disease in adult

life, often in the late 20s to 40s.
Severe from onset, Severe exacerbations with persistent
sputum eosinophilia (>2%), despite corticosteroid therapy.
less clinical allergic responses( non atopic) than earlyonset asthma.
It is often associated with sinus disease.
Genetics:

Few patients in this group have a family
history of asthma.
little is known regarding the genetics of adult
onset persistent asthma.
Biomarkers:
Lung eosinophilia. Persistent sputum eosinophilia (≥2%)

The lack of clinical allergy in this phenotype suggests that the TH2
process differs from and is probably more complex than the one
associated with the early-onset allergic phenotype but the presence
of IL-13 and IL-5 in the lower airways confirm Th2 pathway.
Some individuals show sputum neutrophilia intermixed with their

eosinophilic process. This mixed inflammatory process implies
that there are interactions of additional immune pathways with
TH2 immunity, including activation of pathways related to IL-33
and IL-17 .
Elevations in FeNO
Treatment responses:
• persistent eosinophilia in late-onset disease inspite of ICS implies that
the TH2 process in this type of asthma is refractory to corticosteroids

but high systemic doses of corticosteroids are generally able to
overcome this refractoriness in late-onset asthma.

• IL-5 targeted therapy may show much better efficacy in this
endotype, compared in early-onset allergic asthma patients, as IL-5
dependent eosinophilia may be more important in this potential

endotype. (decreasing exacerbations and systemic corticosteroid
requirements)

• IL-4 and IL-13 targeted therapy pathway.
Aspirin exacerbated airway disease
(AERD)
AERD is probably a subendotype or a similar endotype. It is an

acquired condition on top of an intrinsic or less frequently
allergic asthma and thus, despite its peculiar sensitivity to
NSAIDs, still has major overlap with these conditions.

Clinical characteristics :
•

AERD is frequently progressive severe asthma starts late in
life and is associated with eosinophilia and sinus disease

Polyposis.
• Response to aspirin challenge
Genetics :
•

LT-related gene polymorphisms.

•

Gene-expression study identified upregulation of periostin a potent
regulator of fibrosis and collagen deposition has also been identified
in polyps of and in airway epithelial cells of patients with AIA.
Overexpression of periostin has been associated with accelerated cell
growth and angiogenesis(subtype).

Biomarkers:
high cysteinyl leukotriene level.
Treatment responses :
• Many patients require systemic corticosteroids to control
their sinusitis and asthma.
•

Leukotriene modifiers especially 5-LO inhibitors can have a
robust impact on the AERD subset.

• Downregulation of periostin after treatment of asthmatic
patients with corticosteroids suggests that normalization of
periostin expression is a part of the therapeutic effects of

corticosteroids. This opens a possibility of specifically
targeting periostin in future therapies for nasal polyps and

asthma
Exercise induced asthma
Clinical characteristics:
• Exercise induced asthma refers to asthma whose symptoms
are experienced primarily after exercise. EIA is a milder

form of TH2 asthma.
• Consistent with a relationship to TH2 processes, EIA

common in atopic athletes and high percentages of
eosinophils and mast cells and their mediators .
Biomarkers:
•

Th2 cytokines and cysteinyl leukotriene

Genetics:
•

No distinct genetic factors .

Treatment responses:
• Leukotriene modifiers high LTE4/FENO ratio is Surrogate
marker predicting better response.
•

IL-9 targeted therapy has been shown effective on patients
of this group, which implies that Th2 immunity is involved in
the pathophysiology of EIA.
Non Th2-associated asthma
The lack of efficacy of Th2 targeted therapy suggests that a

subgroup of asthma develops in the absence of Th2 immunity.
Little is understood about the non Th2 asthma and its related
molecular elements.

• Obesity-related asthma
• Neutrophilic asthma
• Smoking asthma
Whether obesity is a driving component in asthma development
or a mere confounder or comorbidity of its presence remains
controversial.

It is likely that obesity differentially impacts asthma that
develops early in life, as compared to later in life, being a more

prominent independent contributor in later onset disease.
So a distinct obesity-related asthma phenotype seems to occur

only in non-TH2 asthma.


,



..
Clinical characteristics :
Patients in this group are commonly women, obese, late onset
(mid-40s), less allergic (obesity is neither a risk factor for atopy
nor a risk factor for allergic asthma).with a high burden of

symptoms.
Biomarkers:
High expression of non Th2 mediators such as tumor



necrosis factor (TNF)-a, IL-6 .

Hormones of obesity, such as adiponectin, leptin, and resistin



either alone or in association with increased oxidative stress.


Elevations in an endogenous inhibitor of iNOS, asymmetric

dimethyl arginine (ADMA).


lower amounts of FeNO, fewer eosinophils.
Treatment responses:


Patients of this subgroup usually respond poorly to corticosteroids.



Bariatric surgery induced weight loss was associated with profound
improvements in lung function and symptoms in obese asthma.



However, the effect of weight loss on bronchial hyper responsiveness
was only shown in late-onset, nonallergic (non-Th2) asthma patient,

consistent with late onset obese asthma being a separate endotype. This
is further supported by the increase in ADMA in association with
worsening severity and control in late onset obese asthma only.
Clinical characteristics and biomarkers:


It remains controversial whether neutrophilia is an independent driving
component, a synergistic factor with eosinophilia or just a consequence of
corticosteroid therapy.



Still unclear whether this represents a unique form of asthma or just a
different stage of severity or persistent bacterial colonization or infection of
the airways on the background of a previously eosinophilic asthma.



Airway pathophysiology in neutrophilic asthma is characterized by (fixed)
airflow limitation
measured by CT) .

more trapping of air, thicker airway walls (as


Novel mechanisms implicated in the pathogenesis of
noneosinophilic asthma involve the activation of innate immune
responses with a possible role of bacteria, viruses.



Neutrophilia can also co-exist with eosinophilia, and this identifies
the people with the most severe asthma and emphasizes the
complexity of the immunobiology of severe asthma in which
multiple different innate and adaptive immune pathways and cells
may have roles.




Impaired nuclear recruitment of histone deacetylase (HDAC).

The role of TH17 immunity
Biomarkers:


IL-8, IL-17A, LTB4, and possibly IL-32.



IL-1 and TNF-α pathways are upregulated and associated with
neutrophilic inflammation in a sputum gene-expression study.



low levels of FeNO.
Treatment responses:



Corticosteroids are less effective in patients of this subgroup.
Macrolide antibiotics may have some efficacy on neutrophilic
asthma, By modulating the innate immune response in the
lung, by reducing the expression of neutrophilic markers .



Restoration of HDAC 2 nuclear recruitment with theophylline.



Anti-TNF-α responsive( infliximab )



The efficacy of IL-17 targeted therapy in this subtype of

asthma awaits evidence from ongoing clinical trials.


Smoking has a complex relationship with asthma. It is
associated with deteriorating lung function and resistance to
corticosteroids.



Smoking asthma has been associated with neutrophilia in lung
tissue.
It is unknown if smoking asthma is a subtype of neutrophilic
asthma or an independent endotype . Since not all smoking
asthma is accompanied by neutrophilia, it is more likely that
there is only a partial overlap between neutrophilic asthma and
smoking asthma.




Some reports have suggested that smoking is associated with

elevated total IgE and that active smoking may increase the risk of
sensitization to workplace allergens.


However, little is understood regarding the role of genetics,

biomarkers or pathobiology.


FeNO levels are decreased by smoking and could help to

differentiate asthmatic subjects from non-asthmatic subjects.

Treatment responses



Quitting smoking
Restoration of HDAC 2 nuclear recruitment with theophylline.
The intensity of the colors represents the range of severity; the relative sizes
of the subcircles suggest relative proportions of affected individuals
Lötvall et al.2011 proposed endotyping asthma into six classes
depending on several parameters used to define an endotype.


Aspirin sensitive asthma



Allergic asthma (adults)



Severe late-onset hypereosinophilic



ABPM



API-positive preschool wheezer



Asthma in cross country skiers
The principle of personalized or individualized medicine is to
'bring the right drug to the right patient at the right dose', such

that therapeutic efficacy is maximized and the side effects are
kept to a minimum.


The consideration of disease endotypes in treatment design
should be able to bridge the present era of treating asthma
based on family history, patient characteristics and laboratory

test, to the future era of personalized medicine where
treatment scheme will be based on individual biological data
such as genomic, proteomic and metabolic profiles.
Asthma phenotypes and endotypes

Contenu connexe

Tendances

Asthma management phenotype based approach
Asthma management phenotype based approachAsthma management phenotype based approach
Asthma management phenotype based approachGamal Agmy
 
difficult to treat asthma.pptx
difficult to treat asthma.pptxdifficult to treat asthma.pptx
difficult to treat asthma.pptxEmil Mohan
 
Interstitial pulmonary fibrosis
Interstitial pulmonary fibrosisInterstitial pulmonary fibrosis
Interstitial pulmonary fibrosisashish ranjan
 
Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.Hiba Ashibany
 
Steroid resistent asthma
Steroid resistent asthmaSteroid resistent asthma
Steroid resistent asthmanaser21021
 
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)Sarfraz Saleemi
 
severe uncontrolled asthma
severe uncontrolled asthma severe uncontrolled asthma
severe uncontrolled asthma mbito1
 
Eosinophillic pneumonia
Eosinophillic pneumoniaEosinophillic pneumonia
Eosinophillic pneumoniaRikin Hasnani
 
Abpa . a diagnostic dilemma
Abpa . a diagnostic dilemmaAbpa . a diagnostic dilemma
Abpa . a diagnostic dilemmaVeerendra Singh
 
Personalised treatment for asthma
Personalised treatment for asthmaPersonalised treatment for asthma
Personalised treatment for asthmaNahid Sherbini
 
Insights in Asthma Rhinitis link
Insights in Asthma Rhinitis link Insights in Asthma Rhinitis link
Insights in Asthma Rhinitis link Ashraf ElAdawy
 
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku Joseph
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku JosephAllergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku Joseph
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku JosephDr.Tinku Joseph
 
Ild seminar ppt
Ild seminar pptIld seminar ppt
Ild seminar pptmikru taye
 
Broncho provocation testing ppt
Broncho provocation testing pptBroncho provocation testing ppt
Broncho provocation testing pptWaseem MD abdul
 

Tendances (20)

Asthma biomarkers: FENO
Asthma biomarkers: FENOAsthma biomarkers: FENO
Asthma biomarkers: FENO
 
Asthma management phenotype based approach
Asthma management phenotype based approachAsthma management phenotype based approach
Asthma management phenotype based approach
 
difficult to treat asthma.pptx
difficult to treat asthma.pptxdifficult to treat asthma.pptx
difficult to treat asthma.pptx
 
Interstitial pulmonary fibrosis
Interstitial pulmonary fibrosisInterstitial pulmonary fibrosis
Interstitial pulmonary fibrosis
 
Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.
 
Steroid resistent asthma
Steroid resistent asthmaSteroid resistent asthma
Steroid resistent asthma
 
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
 
Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
 
Asthma phenotypes
Asthma phenotypesAsthma phenotypes
Asthma phenotypes
 
Hypersensitivity pneumonitis
Hypersensitivity pneumonitisHypersensitivity pneumonitis
Hypersensitivity pneumonitis
 
Abpa
AbpaAbpa
Abpa
 
severe uncontrolled asthma
severe uncontrolled asthma severe uncontrolled asthma
severe uncontrolled asthma
 
Eosinophillic pneumonia
Eosinophillic pneumoniaEosinophillic pneumonia
Eosinophillic pneumonia
 
Abpa . a diagnostic dilemma
Abpa . a diagnostic dilemmaAbpa . a diagnostic dilemma
Abpa . a diagnostic dilemma
 
Personalised treatment for asthma
Personalised treatment for asthmaPersonalised treatment for asthma
Personalised treatment for asthma
 
Dlco/tlco
Dlco/tlcoDlco/tlco
Dlco/tlco
 
Insights in Asthma Rhinitis link
Insights in Asthma Rhinitis link Insights in Asthma Rhinitis link
Insights in Asthma Rhinitis link
 
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku Joseph
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku JosephAllergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku Joseph
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku Joseph
 
Ild seminar ppt
Ild seminar pptIld seminar ppt
Ild seminar ppt
 
Broncho provocation testing ppt
Broncho provocation testing pptBroncho provocation testing ppt
Broncho provocation testing ppt
 

Similaire à Asthma phenotypes and endotypes

Bronchial Asthma and Asthma Control
Bronchial Asthma and Asthma ControlBronchial Asthma and Asthma Control
Bronchial Asthma and Asthma ControlGamal Agmy
 
Asthma updates
Asthma updatesAsthma updates
Asthma updatesGamal Agmy
 
Bronchial Asthma Updates
Bronchial Asthma UpdatesBronchial Asthma Updates
Bronchial Asthma UpdatesGamal Agmy
 
Case_Presentation_on_Management_of_Asthma,_21st_of_July_2023.pptx
Case_Presentation_on_Management_of_Asthma,_21st_of_July_2023.pptxCase_Presentation_on_Management_of_Asthma,_21st_of_July_2023.pptx
Case_Presentation_on_Management_of_Asthma,_21st_of_July_2023.pptxAbduWereka
 
Asthma PREPARED BY ENDLA SRINIVASA RAO DEPT OF MEDICAL SURGICAL NURSING
Asthma PREPARED BY ENDLA SRINIVASA RAO DEPT OF MEDICAL SURGICAL NURSING Asthma PREPARED BY ENDLA SRINIVASA RAO DEPT OF MEDICAL SURGICAL NURSING
Asthma PREPARED BY ENDLA SRINIVASA RAO DEPT OF MEDICAL SURGICAL NURSING Endla Srini
 
2.1. Bronchial asthma new.pptx
2.1. Bronchial asthma new.pptx2.1. Bronchial asthma new.pptx
2.1. Bronchial asthma new.pptxAkshaydeep25
 
New asthma ppp modified 2011
New asthma ppp modified 2011New asthma ppp modified 2011
New asthma ppp modified 2011JohnScreen
 
Bronchial Asthma.pdf
 Bronchial Asthma.pdf Bronchial Asthma.pdf
Bronchial Asthma.pdfRahulraut94
 
Asthma presentation and management
Asthma presentation  and managementAsthma presentation  and management
Asthma presentation and managementsimeon joseph
 
pharmacology of asthma
pharmacology of asthmapharmacology of asthma
pharmacology of asthmasimeon joseph
 

Similaire à Asthma phenotypes and endotypes (20)

Bronchial Asthma and Asthma Control
Bronchial Asthma and Asthma ControlBronchial Asthma and Asthma Control
Bronchial Asthma and Asthma Control
 
Asthma updates
Asthma updatesAsthma updates
Asthma updates
 
Bronchial Asthma Updates
Bronchial Asthma UpdatesBronchial Asthma Updates
Bronchial Asthma Updates
 
Case_Presentation_on_Management_of_Asthma,_21st_of_July_2023.pptx
Case_Presentation_on_Management_of_Asthma,_21st_of_July_2023.pptxCase_Presentation_on_Management_of_Asthma,_21st_of_July_2023.pptx
Case_Presentation_on_Management_of_Asthma,_21st_of_July_2023.pptx
 
Asthma PREPARED BY ENDLA SRINIVASA RAO DEPT OF MEDICAL SURGICAL NURSING
Asthma PREPARED BY ENDLA SRINIVASA RAO DEPT OF MEDICAL SURGICAL NURSING Asthma PREPARED BY ENDLA SRINIVASA RAO DEPT OF MEDICAL SURGICAL NURSING
Asthma PREPARED BY ENDLA SRINIVASA RAO DEPT OF MEDICAL SURGICAL NURSING
 
Asthma phenotypes
Asthma phenotypesAsthma phenotypes
Asthma phenotypes
 
Refractory asthma
Refractory asthmaRefractory asthma
Refractory asthma
 
ASTHMA.pptx
ASTHMA.pptxASTHMA.pptx
ASTHMA.pptx
 
2.1. Bronchial asthma new.pptx
2.1. Bronchial asthma new.pptx2.1. Bronchial asthma new.pptx
2.1. Bronchial asthma new.pptx
 
Asthma.pptx
Asthma.pptxAsthma.pptx
Asthma.pptx
 
New asthma ppp modified 2011
New asthma ppp modified 2011New asthma ppp modified 2011
New asthma ppp modified 2011
 
Bronchial asthma
Bronchial asthmaBronchial asthma
Bronchial asthma
 
Asthma phenotypes.pptx
Asthma phenotypes.pptxAsthma phenotypes.pptx
Asthma phenotypes.pptx
 
Bronchial Asthma.pdf
 Bronchial Asthma.pdf Bronchial Asthma.pdf
Bronchial Asthma.pdf
 
Asthma presentation and management
Asthma presentation  and managementAsthma presentation  and management
Asthma presentation and management
 
Bronchial Asthma.pptx
Bronchial Asthma.pptxBronchial Asthma.pptx
Bronchial Asthma.pptx
 
pharmacology of asthma
pharmacology of asthmapharmacology of asthma
pharmacology of asthma
 
Approach to asthma
Approach to asthmaApproach to asthma
Approach to asthma
 
Approach to asthma
Approach to asthmaApproach to asthma
Approach to asthma
 
Asthma
AsthmaAsthma
Asthma
 

Plus de Gamal Agmy

Snap Shots in ILDs.ppt
Snap Shots in ILDs.pptSnap Shots in ILDs.ppt
Snap Shots in ILDs.pptGamal Agmy
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 1)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 1)Antibiotic Strategy in Lower Respiratory Tract Infections (part 1)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 1)Gamal Agmy
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Gamal Agmy
 
Radiological Presentation of COVID 19
Radiological Presentation of COVID 19Radiological Presentation of COVID 19
Radiological Presentation of COVID 19Gamal Agmy
 
Antibiotic Strategy in Lower Respiratory Tract Infections
Antibiotic Strategy in Lower Respiratory Tract InfectionsAntibiotic Strategy in Lower Respiratory Tract Infections
Antibiotic Strategy in Lower Respiratory Tract InfectionsGamal Agmy
 
Imaging of Pulmonary Vascular Lesions ``
Imaging of Pulmonary Vascular Lesions ``Imaging of Pulmonary Vascular Lesions ``
Imaging of Pulmonary Vascular Lesions ``Gamal Agmy
 
Pneumomediastinum
PneumomediastinumPneumomediastinum
PneumomediastinumGamal Agmy
 
Management Dilemmas in Acute Pulmonary Embolism
Management Dilemmas in Acute Pulmonary Embolism Management Dilemmas in Acute Pulmonary Embolism
Management Dilemmas in Acute Pulmonary Embolism Gamal Agmy
 
Imaging of Mediastinum
Imaging of MediastinumImaging of Mediastinum
Imaging of MediastinumGamal Agmy
 
Imaging of pulmonary vascular lesions
Imaging of pulmonary vascular lesionsImaging of pulmonary vascular lesions
Imaging of pulmonary vascular lesionsGamal Agmy
 
Transthoacic Sonography
Transthoacic SonographyTransthoacic Sonography
Transthoacic SonographyGamal Agmy
 
:Weaning from Mechanical Ventilation :Recent Updates
:Weaning from Mechanical Ventilation :Recent Updates:Weaning from Mechanical Ventilation :Recent Updates
:Weaning from Mechanical Ventilation :Recent UpdatesGamal Agmy
 
Radiological Presentation of Pulmonary Pathology
Radiological Presentation of Pulmonary PathologyRadiological Presentation of Pulmonary Pathology
Radiological Presentation of Pulmonary PathologyGamal Agmy
 
Oxygen Therapy is not Beneficial in COPD Patients with Moderate Hypoxaemia
Oxygen Therapy is not  Beneficial in COPD Patients with Moderate HypoxaemiaOxygen Therapy is not  Beneficial in COPD Patients with Moderate Hypoxaemia
Oxygen Therapy is not Beneficial in COPD Patients with Moderate HypoxaemiaGamal Agmy
 
Using Imaging as a Biomarker for Asthma
Using Imaging as a Biomarker for AsthmaUsing Imaging as a Biomarker for Asthma
Using Imaging as a Biomarker for AsthmaGamal Agmy
 
Discontinuing Mechanical Ventilation in ICU
Discontinuing Mechanical Ventilation in ICUDiscontinuing Mechanical Ventilation in ICU
Discontinuing Mechanical Ventilation in ICUGamal Agmy
 
Ultrasound in ICU and Emergency
Ultrasound in ICU and EmergencyUltrasound in ICU and Emergency
Ultrasound in ICU and EmergencyGamal Agmy
 
Arterial Blood Gases Analysis
Arterial Blood Gases AnalysisArterial Blood Gases Analysis
Arterial Blood Gases AnalysisGamal Agmy
 
Updates in Diagnosis of COPD
Updates in Diagnosis of COPDUpdates in Diagnosis of COPD
Updates in Diagnosis of COPDGamal Agmy
 

Plus de Gamal Agmy (20)

Snap Shots in ILDs.ppt
Snap Shots in ILDs.pptSnap Shots in ILDs.ppt
Snap Shots in ILDs.ppt
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 1)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 1)Antibiotic Strategy in Lower Respiratory Tract Infections (part 1)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 1)
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
 
Radiological Presentation of COVID 19
Radiological Presentation of COVID 19Radiological Presentation of COVID 19
Radiological Presentation of COVID 19
 
COVID 19
COVID 19  COVID 19
COVID 19
 
Antibiotic Strategy in Lower Respiratory Tract Infections
Antibiotic Strategy in Lower Respiratory Tract InfectionsAntibiotic Strategy in Lower Respiratory Tract Infections
Antibiotic Strategy in Lower Respiratory Tract Infections
 
Imaging of Pulmonary Vascular Lesions ``
Imaging of Pulmonary Vascular Lesions ``Imaging of Pulmonary Vascular Lesions ``
Imaging of Pulmonary Vascular Lesions ``
 
Pneumomediastinum
PneumomediastinumPneumomediastinum
Pneumomediastinum
 
Management Dilemmas in Acute Pulmonary Embolism
Management Dilemmas in Acute Pulmonary Embolism Management Dilemmas in Acute Pulmonary Embolism
Management Dilemmas in Acute Pulmonary Embolism
 
Imaging of Mediastinum
Imaging of MediastinumImaging of Mediastinum
Imaging of Mediastinum
 
Imaging of pulmonary vascular lesions
Imaging of pulmonary vascular lesionsImaging of pulmonary vascular lesions
Imaging of pulmonary vascular lesions
 
Transthoacic Sonography
Transthoacic SonographyTransthoacic Sonography
Transthoacic Sonography
 
:Weaning from Mechanical Ventilation :Recent Updates
:Weaning from Mechanical Ventilation :Recent Updates:Weaning from Mechanical Ventilation :Recent Updates
:Weaning from Mechanical Ventilation :Recent Updates
 
Radiological Presentation of Pulmonary Pathology
Radiological Presentation of Pulmonary PathologyRadiological Presentation of Pulmonary Pathology
Radiological Presentation of Pulmonary Pathology
 
Oxygen Therapy is not Beneficial in COPD Patients with Moderate Hypoxaemia
Oxygen Therapy is not  Beneficial in COPD Patients with Moderate HypoxaemiaOxygen Therapy is not  Beneficial in COPD Patients with Moderate Hypoxaemia
Oxygen Therapy is not Beneficial in COPD Patients with Moderate Hypoxaemia
 
Using Imaging as a Biomarker for Asthma
Using Imaging as a Biomarker for AsthmaUsing Imaging as a Biomarker for Asthma
Using Imaging as a Biomarker for Asthma
 
Discontinuing Mechanical Ventilation in ICU
Discontinuing Mechanical Ventilation in ICUDiscontinuing Mechanical Ventilation in ICU
Discontinuing Mechanical Ventilation in ICU
 
Ultrasound in ICU and Emergency
Ultrasound in ICU and EmergencyUltrasound in ICU and Emergency
Ultrasound in ICU and Emergency
 
Arterial Blood Gases Analysis
Arterial Blood Gases AnalysisArterial Blood Gases Analysis
Arterial Blood Gases Analysis
 
Updates in Diagnosis of COPD
Updates in Diagnosis of COPDUpdates in Diagnosis of COPD
Updates in Diagnosis of COPD
 

Dernier

Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 

Dernier (20)

Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 

Asthma phenotypes and endotypes

  • 2. Asthma Phenotypes and Endotypes Gamal Rabie Agmy, MD, FCCP Professor of chest Diseases, Assiut university
  • 3. Definition of Asthma  A chronic inflammatory disorder of the airways  Many cells and cellular elements play a role  Chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing  Widespread, variable, and often reversible airflow limitation
  • 4. Asthma Inflammation: Cells and Mediators Source: Peter J. Barnes, MD
  • 5.  Asthma is a complex disease or a syndrome that includes several disease variants. The term asthma, like ‘arthritis’, equates to a definition of grouped clinical and physiological characteristics. These characteristics could identify syndromes, phenotypes or even multiple diseases rather than a single disease.
  • 6. ◙ For revealing the complexity and the heterogeneity of this disease, asthma patients were grouped into subtypes called phenotypes. ◙ Term ‘phenotype’ describes subtypes of asthma focused on ‘clinically observable characteristics’ of a disease.
  • 10. Therefore, there are many ‘definitions’ for asthma phenotypes, many of which are related to differences in symptoms and severity rather than to differences in underlying mechanisms. but this kind of subtyping does little to help understand prognosis and target therapy. When a link can be made between clinical characteristics and molecular pathways, the term endotype can be introduced to describe distinct subtypes with a defining etiology and consistent pathobiologic mechanisms.
  • 11. The definition of a true phenotype (or endotype) requires an underlying pathobiology with identifiable biomarkers and genetics . Gene-expression profiling allows definition of expression signatures to characterize patient subgroups, predict response to treatment, and offer novel therapies.
  • 12. Th2-associated asthma These patients are characterized by atopy, eosinophilic inflammation and favorable response to corticosteroids. Early-onset allergic asthma Late-onset persistent eosinophilic asthma Exercise induced asthma
  • 13. Early-onset allergic asthma Clinical characteristics: This group of asthmatic patients developed their disease in childhood, and maintained their symptoms into adulthood. . The majority of early-onset allergic asthma is mild but that an increasing complexity of immune processes leads to greater severity. Most people with asthma are likely to have this phenotype. Positive skin prick tests, specific IgE antibodies in serum, eosinophilia in the peripheral blood .
  • 14. Genetics: Early-onset allergic patients commonly have a family history of asthma, suggesting a genetic component. ►Several Th2 cytokine SNPs ►higher numbers of mutations in TH2-related genes (IL4, IL13, IL4Rα ) associated with greater severity of disease.
  • 15. Biomarkers: Positive SPT, elevated IgE/elevated FeNO Th2 cytokines IL-4 ,IL-5 , IL-9, IL-13, and periostin measured in sputum, BAL, serum and bronchial biopsies. Treatment responses: ►Corticosteroid-responsive. ►Th2 Targeted therapy: Anti IgE (omalizumab)in Severe allergic asthma. Anti–IL-13( lebrikizumab) in Allergic asthma with dominant IL13 activation . Surrogate marker predicting better response is high circulating levels of periostin. .
  • 16. Inhaled IL-4Rα antagonist . Surrogate marker predicting better response is IL-4 receptor a polymorphism.
  • 17. Late-onset persistent eosinophilic asthma Clinical characteristics: The majority of this group develops disease in adult life, often in the late 20s to 40s. Severe from onset, Severe exacerbations with persistent sputum eosinophilia (>2%), despite corticosteroid therapy. less clinical allergic responses( non atopic) than earlyonset asthma. It is often associated with sinus disease.
  • 18. Genetics: Few patients in this group have a family history of asthma. little is known regarding the genetics of adult onset persistent asthma.
  • 19. Biomarkers: Lung eosinophilia. Persistent sputum eosinophilia (≥2%) The lack of clinical allergy in this phenotype suggests that the TH2 process differs from and is probably more complex than the one associated with the early-onset allergic phenotype but the presence of IL-13 and IL-5 in the lower airways confirm Th2 pathway. Some individuals show sputum neutrophilia intermixed with their eosinophilic process. This mixed inflammatory process implies that there are interactions of additional immune pathways with TH2 immunity, including activation of pathways related to IL-33 and IL-17 . Elevations in FeNO
  • 20. Treatment responses: • persistent eosinophilia in late-onset disease inspite of ICS implies that the TH2 process in this type of asthma is refractory to corticosteroids but high systemic doses of corticosteroids are generally able to overcome this refractoriness in late-onset asthma. • IL-5 targeted therapy may show much better efficacy in this endotype, compared in early-onset allergic asthma patients, as IL-5 dependent eosinophilia may be more important in this potential endotype. (decreasing exacerbations and systemic corticosteroid requirements) • IL-4 and IL-13 targeted therapy pathway.
  • 21. Aspirin exacerbated airway disease (AERD) AERD is probably a subendotype or a similar endotype. It is an acquired condition on top of an intrinsic or less frequently allergic asthma and thus, despite its peculiar sensitivity to NSAIDs, still has major overlap with these conditions. Clinical characteristics : • AERD is frequently progressive severe asthma starts late in life and is associated with eosinophilia and sinus disease Polyposis. • Response to aspirin challenge
  • 22. Genetics : • LT-related gene polymorphisms. • Gene-expression study identified upregulation of periostin a potent regulator of fibrosis and collagen deposition has also been identified in polyps of and in airway epithelial cells of patients with AIA. Overexpression of periostin has been associated with accelerated cell growth and angiogenesis(subtype). Biomarkers: high cysteinyl leukotriene level.
  • 23. Treatment responses : • Many patients require systemic corticosteroids to control their sinusitis and asthma. • Leukotriene modifiers especially 5-LO inhibitors can have a robust impact on the AERD subset. • Downregulation of periostin after treatment of asthmatic patients with corticosteroids suggests that normalization of periostin expression is a part of the therapeutic effects of corticosteroids. This opens a possibility of specifically targeting periostin in future therapies for nasal polyps and asthma
  • 24. Exercise induced asthma Clinical characteristics: • Exercise induced asthma refers to asthma whose symptoms are experienced primarily after exercise. EIA is a milder form of TH2 asthma. • Consistent with a relationship to TH2 processes, EIA common in atopic athletes and high percentages of eosinophils and mast cells and their mediators .
  • 25. Biomarkers: • Th2 cytokines and cysteinyl leukotriene Genetics: • No distinct genetic factors . Treatment responses: • Leukotriene modifiers high LTE4/FENO ratio is Surrogate marker predicting better response. • IL-9 targeted therapy has been shown effective on patients of this group, which implies that Th2 immunity is involved in the pathophysiology of EIA.
  • 26. Non Th2-associated asthma The lack of efficacy of Th2 targeted therapy suggests that a subgroup of asthma develops in the absence of Th2 immunity. Little is understood about the non Th2 asthma and its related molecular elements. • Obesity-related asthma • Neutrophilic asthma • Smoking asthma
  • 27. Whether obesity is a driving component in asthma development or a mere confounder or comorbidity of its presence remains controversial. It is likely that obesity differentially impacts asthma that develops early in life, as compared to later in life, being a more prominent independent contributor in later onset disease. So a distinct obesity-related asthma phenotype seems to occur only in non-TH2 asthma.  ,  ..
  • 28. Clinical characteristics : Patients in this group are commonly women, obese, late onset (mid-40s), less allergic (obesity is neither a risk factor for atopy nor a risk factor for allergic asthma).with a high burden of symptoms.
  • 29. Biomarkers: High expression of non Th2 mediators such as tumor  necrosis factor (TNF)-a, IL-6 . Hormones of obesity, such as adiponectin, leptin, and resistin  either alone or in association with increased oxidative stress.  Elevations in an endogenous inhibitor of iNOS, asymmetric dimethyl arginine (ADMA).  lower amounts of FeNO, fewer eosinophils.
  • 30. Treatment responses:  Patients of this subgroup usually respond poorly to corticosteroids.  Bariatric surgery induced weight loss was associated with profound improvements in lung function and symptoms in obese asthma.  However, the effect of weight loss on bronchial hyper responsiveness was only shown in late-onset, nonallergic (non-Th2) asthma patient, consistent with late onset obese asthma being a separate endotype. This is further supported by the increase in ADMA in association with worsening severity and control in late onset obese asthma only.
  • 31. Clinical characteristics and biomarkers:  It remains controversial whether neutrophilia is an independent driving component, a synergistic factor with eosinophilia or just a consequence of corticosteroid therapy.  Still unclear whether this represents a unique form of asthma or just a different stage of severity or persistent bacterial colonization or infection of the airways on the background of a previously eosinophilic asthma.  Airway pathophysiology in neutrophilic asthma is characterized by (fixed) airflow limitation measured by CT) . more trapping of air, thicker airway walls (as
  • 32.  Novel mechanisms implicated in the pathogenesis of noneosinophilic asthma involve the activation of innate immune responses with a possible role of bacteria, viruses.  Neutrophilia can also co-exist with eosinophilia, and this identifies the people with the most severe asthma and emphasizes the complexity of the immunobiology of severe asthma in which multiple different innate and adaptive immune pathways and cells may have roles.   Impaired nuclear recruitment of histone deacetylase (HDAC). The role of TH17 immunity
  • 33. Biomarkers:  IL-8, IL-17A, LTB4, and possibly IL-32.  IL-1 and TNF-α pathways are upregulated and associated with neutrophilic inflammation in a sputum gene-expression study.  low levels of FeNO.
  • 34. Treatment responses:   Corticosteroids are less effective in patients of this subgroup. Macrolide antibiotics may have some efficacy on neutrophilic asthma, By modulating the innate immune response in the lung, by reducing the expression of neutrophilic markers .  Restoration of HDAC 2 nuclear recruitment with theophylline.  Anti-TNF-α responsive( infliximab )  The efficacy of IL-17 targeted therapy in this subtype of asthma awaits evidence from ongoing clinical trials.
  • 35.  Smoking has a complex relationship with asthma. It is associated with deteriorating lung function and resistance to corticosteroids.  Smoking asthma has been associated with neutrophilia in lung tissue. It is unknown if smoking asthma is a subtype of neutrophilic asthma or an independent endotype . Since not all smoking asthma is accompanied by neutrophilia, it is more likely that there is only a partial overlap between neutrophilic asthma and smoking asthma. 
  • 36.  Some reports have suggested that smoking is associated with elevated total IgE and that active smoking may increase the risk of sensitization to workplace allergens.  However, little is understood regarding the role of genetics, biomarkers or pathobiology.  FeNO levels are decreased by smoking and could help to differentiate asthmatic subjects from non-asthmatic subjects. Treatment responses   Quitting smoking Restoration of HDAC 2 nuclear recruitment with theophylline.
  • 37. The intensity of the colors represents the range of severity; the relative sizes of the subcircles suggest relative proportions of affected individuals
  • 38. Lötvall et al.2011 proposed endotyping asthma into six classes depending on several parameters used to define an endotype.  Aspirin sensitive asthma  Allergic asthma (adults)  Severe late-onset hypereosinophilic  ABPM  API-positive preschool wheezer  Asthma in cross country skiers
  • 39. The principle of personalized or individualized medicine is to 'bring the right drug to the right patient at the right dose', such that therapeutic efficacy is maximized and the side effects are kept to a minimum.
  • 40.  The consideration of disease endotypes in treatment design should be able to bridge the present era of treating asthma based on family history, patient characteristics and laboratory test, to the future era of personalized medicine where treatment scheme will be based on individual biological data such as genomic, proteomic and metabolic profiles.